Welcome to our dedicated page for Celgene SEC filings (Ticker: CELG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celgene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celgene's regulatory disclosures and financial reporting.
Bristol Myers Squibb executive Adam Lenkowsky reported multiple stock-based compensation events involving common stock and performance-linked awards. On March 10, 2026, he exercised or settled derivative awards covering 24,071 shares tied to market share units and performance shares, with no open‑market purchases or sales.
The filing shows 7,015 common shares withheld at $60.13 per share to satisfy tax obligations as awards vested. Lenkowsky also received new long-term incentives, including 32,653 market share units and 48,980 performance share units scheduled to run to 2029, all linked to Bristol Myers Squibb common stock.
After these transactions, he directly holds 19,135 shares of common stock, plus indirect holdings of 5,849.47 shares through a BMS savings and investment program and 2,929 shares held by his spouse. Footnotes clarify these events reflect routine vesting, performance adjustments, and tax withholding under the company’s long-term incentive plans.
Bristol Myers Squibb executive Adam Lenkowsky reported multiple stock-based compensation events involving common stock and performance-linked awards. On March 10, 2026, he exercised or settled derivative awards covering 24,071 shares tied to market share units and performance shares, with no open‑market purchases or sales.
The filing shows 7,015 common shares withheld at $60.13 per share to satisfy tax obligations as awards vested. Lenkowsky also received new long-term incentives, including 32,653 market share units and 48,980 performance share units scheduled to run to 2029, all linked to Bristol Myers Squibb common stock.
After these transactions, he directly holds 19,135 shares of common stock, plus indirect holdings of 5,849.47 shares through a BMS savings and investment program and 2,929 shares held by his spouse. Footnotes clarify these events reflect routine vesting, performance adjustments, and tax withholding under the company’s long-term incentive plans.
Bristol Myers Squibb SVP and Controller Phil M. Holzer reported multiple equity award transactions in company stock and units on March 10, 2026. He exercised market share units and performance shares covering 6,191 shares of common stock and received new grants of 5,031 market share units and 7,547 performance share units under long-term incentive programs.
The filing shows vesting and performance-based adjustments to prior awards, along with 1,358 common shares withheld at $60.13 per share to cover tax obligations. Following these compensation-related transactions, Holzer directly holds 17,362 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb SVP and Controller Phil M. Holzer reported multiple equity award transactions in company stock and units on March 10, 2026. He exercised market share units and performance shares covering 6,191 shares of common stock and received new grants of 5,031 market share units and 7,547 performance share units under long-term incentive programs.
The filing shows vesting and performance-based adjustments to prior awards, along with 1,358 common shares withheld at $60.13 per share to cover tax obligations. Following these compensation-related transactions, Holzer directly holds 17,362 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb President, Cell Therapy Org. Lynelle Hoch reported multiple equity compensation transactions in company stock. On March 10, 2026, she exercised derivative awards, including market share units and performance shares, converting them into a total of 8,192 shares of common stock.
The filing also shows new grants of 6,531 market share units and 9,796 performance share units, each tied to future performance measurement periods and vesting dates through 2029. A total of 1,391 common shares were withheld at $60.13 per share to cover tax obligations upon vesting. Following these transactions, Hoch directly holds 8,210 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb President, Cell Therapy Org. Lynelle Hoch reported multiple equity compensation transactions in company stock. On March 10, 2026, she exercised derivative awards, including market share units and performance shares, converting them into a total of 8,192 shares of common stock.
The filing also shows new grants of 6,531 market share units and 9,796 performance share units, each tied to future performance measurement periods and vesting dates through 2029. A total of 1,391 common shares were withheld at $60.13 per share to cover tax obligations upon vesting. Following these transactions, Hoch directly holds 8,210 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Cari Gallman reported multiple equity-compensation transactions tied to prior and new long‑term incentive awards. On March 10, 2026, she exercised or converted derivative awards into a total of 6,980 shares of common stock, reflecting vesting of earlier market share units and performance shares granted in prior years.
The company withheld 2,165 shares at a price of $60.13 per share to cover tax obligations upon vesting, which is not an open‑market sale. Gallman also received new grants of 26,122 market share units and 39,184 performance share units that run through 2029, with payouts based on multi‑year stock price and performance formulas described in the award terms.
Bristol Myers Squibb executive Cari Gallman reported multiple equity-compensation transactions tied to prior and new long‑term incentive awards. On March 10, 2026, she exercised or converted derivative awards into a total of 6,980 shares of common stock, reflecting vesting of earlier market share units and performance shares granted in prior years.
The company withheld 2,165 shares at a price of $60.13 per share to cover tax obligations upon vesting, which is not an open‑market sale. Gallman also received new grants of 26,122 market share units and 39,184 performance share units that run through 2029, with payouts based on multi‑year stock price and performance formulas described in the award terms.
Bristol Myers Squibb executive vice president and chief people officer Amanda Poole Ahn reported several equity award events tied to performance-based compensation. On March 10, 2026, derivatives representing 6,436 shares of common stock were converted upon vesting of market share units and performance shares.
The company withheld 1,992 shares of common stock at $60.13 per share to cover tax obligations tied to these awards. Ahn also received new long-term incentives: 15,347 market share units and 23,020 performance share units, both scheduled to run to 2029 under performance-based payout structures.
Following these transactions, Ahn holds 7,094 shares of common stock directly and an additional 221.82 shares indirectly through the BMS Savings and Investment Program, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Bristol Myers Squibb executive vice president and chief people officer Amanda Poole Ahn reported several equity award events tied to performance-based compensation. On March 10, 2026, derivatives representing 6,436 shares of common stock were converted upon vesting of market share units and performance shares.
The company withheld 1,992 shares of common stock at $60.13 per share to cover tax obligations tied to these awards. Ahn also received new long-term incentives: 15,347 market share units and 23,020 performance share units, both scheduled to run to 2029 under performance-based payout structures.
Following these transactions, Ahn holds 7,094 shares of common stock directly and an additional 221.82 shares indirectly through the BMS Savings and Investment Program, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Bristol Myers Squibb Chief Executive Officer Christopher S. Boerner reported multiple equity compensation transactions involving common stock and share units. On 2026-03-10, he exercised or settled 71,537 market share and performance share units into common stock and had 21,229 shares withheld at $60.13 per share to cover tax obligations and exercise costs.
He also received new long-term incentives, including 104,490 market share units and 156,735 performance share units that vest or convert based on multi-year performance conditions and Board certification. After these transactions, Boerner held 21,451 shares of common stock directly and 125,439 shares indirectly through a trust, reflecting compensation-related awards and routine tax withholding rather than open-market trading.
Bristol Myers Squibb Chief Executive Officer Christopher S. Boerner reported multiple equity compensation transactions involving common stock and share units. On 2026-03-10, he exercised or settled 71,537 market share and performance share units into common stock and had 21,229 shares withheld at $60.13 per share to cover tax obligations and exercise costs.
He also received new long-term incentives, including 104,490 market share units and 156,735 performance share units that vest or convert based on multi-year performance conditions and Board certification. After these transactions, Boerner held 21,451 shares of common stock directly and 125,439 shares indirectly through a trust, reflecting compensation-related awards and routine tax withholding rather than open-market trading.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular and neuroscience, generating $48,194 million in revenues for the year ended December 31, 2025, roughly flat versus 2024 and up from 2023.
The business is anchored by growth brands such as Opdivo, Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy, supported by broad patent and regulatory exclusivity across the U.S., EU and Japan. Legacy products including Revlimid, Pomalyst, Sprycel and Abraxane face generic erosion in key markets.
The company invested heavily in innovation, with $10.0 billion of R&D expense in 2025 and a pipeline of more than 45 assets across small molecules, biologics, ADCs, CAR-T and radiopharmaceuticals. New and expanded manufacturing facilities for cell therapies and radiopharmaceuticals were brought online in the U.S. and Europe.
Regulatory and pricing pressures are intensifying. Specific products, including Eliquis and Pomalyst, are subject to government-set Medicare prices under the Inflation Reduction Act, and Orencia has been selected for future “negotiation.” A 2025 agreement with the U.S. government adds further concessions, including providing Eliquis free to Medicaid and offering substantial direct-to-patient discounts on several brands.
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular and neuroscience, generating $48,194 million in revenues for the year ended December 31, 2025, roughly flat versus 2024 and up from 2023.
The business is anchored by growth brands such as Opdivo, Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy, supported by broad patent and regulatory exclusivity across the U.S., EU and Japan. Legacy products including Revlimid, Pomalyst, Sprycel and Abraxane face generic erosion in key markets.
The company invested heavily in innovation, with $10.0 billion of R&D expense in 2025 and a pipeline of more than 45 assets across small molecules, biologics, ADCs, CAR-T and radiopharmaceuticals. New and expanded manufacturing facilities for cell therapies and radiopharmaceuticals were brought online in the U.S. and Europe.
Regulatory and pricing pressures are intensifying. Specific products, including Eliquis and Pomalyst, are subject to government-set Medicare prices under the Inflation Reduction Act, and Orencia has been selected for future “negotiation.” A 2025 agreement with the U.S. government adds further concessions, including providing Eliquis free to Medicaid and offering substantial direct-to-patient discounts on several brands.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.